-- Increases Sales and Earnings Projections for 2005 Full Year --
LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc.
(NYSE:HSP), one of the largest hospital products manufacturers in
the United States, today reported results for the second quarter
ended June 30, 2005. Second-Quarter 2005 Financial Summary -- Net
sales were $661.9 million, 0.8 percent below the second quarter of
2004. -- Net income was $72.0 million, compared to $125.8 million
in the same quarter of 2004. Diluted earnings per share were $0.44
versus $0.80 in the prior year's second quarter. -- Included in the
2005 diluted earnings per share are $0.05 for non- recurring
transition expenses related to building the company's independent
infrastructure, and $0.06 per share for obligations assumed as part
of the divestiture of the Salt Lake City manufacturing plant.
Included in the 2004 diluted earnings per share are a one-time,
non-cash curtailment gain of $0.26 related to the discontinuance of
one of Hospira's U.S. post-retirement employee benefit programs,
and non-recurring transition expenses of $0.02 per share related to
building the company's independent infrastructure. "We are pleased
with our second-quarter results -- both sales and the gross margin
exceeded our expectations," said Christopher B. Begley, chief
executive officer, Hospira. "Once again, our performance is a clear
indication that Hospira employees are meeting the challenges for
2005 and are a key asset in driving the success of our business.
With some significant transition milestones behind us and solid
first half numbers, we are increasing our projections for the full
year." Significant Events in the Second Quarter -- Launched the
international regional headquarters for Europe, the Middle East and
Africa (EMEA) in Amsterdam, and for Canada in Montreal. These are
the first of four regional hubs that will support Hospira's
operations outside the United States. -- Announced an agreement to
acquire Physiometrix, Inc., a NASDAQ-listed medical device
manufacturer, which subsequently closed on July 29. The acquisition
will broaden Hospira's portfolio of products for the hospital
operating room and intensive care unit, providing anesthesia-
monitoring devices used during surgical and diagnostic procedures.
-- Launched the wireless version of the Hospira MedNet(TM) system
for the Plum A+(R) infusion pump platform. The new wireless version
establishes real-time send-and-receive capability and links to the
hospital information system network. The Hospira MedNet medication
management software system provides scalable and upgradeable
options for hospitals of varying size and technological needs. --
Held the company's first Annual Meeting of Shareholders, at which
three directors were elected to three-year terms on Hospira's
board, including Judith C. Pelham as a new director. Ms. Pelham
previously served as president and chief executive officer of
Trinity Health until her retirement in 2004. -- Completed the sale
of the Salt Lake City manufacturing facility to ICU Medical. This
transaction enables Hospira to combine its sales and marketing
capabilities with ICU Medical's expertise in cost-efficient custom
manufacturing, allowing Hospira to better address customer needs
for a more specialized critical care product line. The transaction
also reinforces Hospira's continued commitment to optimize
manufacturing productivity and improve efficiencies across its
operations, a critical element of the company's stated strategy to
improve margins and cash flow. Financial and Operating Review
Results for the second quarter of 2005 reflect the company's status
as an independent public company; the second quarter of 2004
reflects results for the business operated as a part of Abbott
Laboratories for the month of April and as a stand-alone business
in May and June. Certain results in this press release are
discussed on both a generally accepted accounting principles (GAAP)
and a non-GAAP (adjusted) basis. A description and reconciliation
of the adjusted financial information to the most comparable GAAP
measurement is provided in the section "Use of Non-GAAP Financial
Measures" contained in this press release. Consolidated net sales
in the second quarter of 2005 decreased 0.8 percent to $661.9
million, compared to $667.4 million in the second quarter of 2004.
A schedule detailing sales by product line for the second quarter
and first six months of 2005 and 2004 is attached to this press
release. In the second quarter of 2005, compared to the same
quarter of 2004, consolidated net sales were negatively affected
1.0 percentage point by the decline in sales to Abbott. The decline
resulted from the exclusion of the bulk drug cost for certain
products subsequent to the spin-off, and decreased demand.
Consolidated net sales were favorably affected 0.2 percentage
points by growth in sales to third parties, driven by: -- Volume
and mix (excluding Berlex) -- 3.1 percentage points, -- Favorable
pricing -- 1.5 percentage points, -- Foreign currency translation
-- 0.6 percentage points, and -- Wind-down of the Berlex agreement
to distribute its imaging agents -- (5.0) percentage points. The
"wind-down" of the company's agreement to distribute the low-margin
Berlex imaging agents was completed in the second quarter, and no
additional sales are expected to be generated during the remainder
of the year. Gross profit in the quarter was $218.4 million, an
increase of 3.7 percent from $210.6 million in the same period last
year. Gross margin in the second quarter of 2005 was 33.0 percent,
compared to 31.6 percent in the prior year's second quarter.
Adjusted* gross profit was $233.6 million in the second quarter of
2005, or 35.3 percent of sales, compared to $211.5 million in the
same quarter of 2004, or 31.7 percent of sales. The adjusted* gross
margin increase was primarily attributable to: -- Wind-down of the
Berlex agreement -- 1.3 percentage points, -- Improved volume and
mix (excluding Berlex) -- 1.2 percentage points, -- Favorable
pricing on sales -- 1.0 percentage point, and -- Inclusion of a
profit on the sales to Abbott subsequent to the spin- off -- 0.6
percentage points. (Sales to Abbott were recorded at cost for the
month of April in the second quarter of 2004.) The increases were
partially offset by additional depreciation of (0.5) percentage
points resulting from the 2004 revision in the estimated useful
life for certain drug delivery pumps placed with customers.
Research and development (R&D) expense rose 17.0 percent in the
quarter to $32.9 million, or 5.0 percent of sales, compared to
$28.1 million, or 4.2 percent of sales, in the second quarter of
2004. The company continues to increase its investment in R&D
as part of its stated strategy to build its new product pipeline to
drive longer-term sales growth. Selling, general and administrative
(S,G&A) expense in the quarter was $87.4 million, compared to
$66.9 million in the 2004 second quarter. As a percentage of sales,
S,G&A was 13.2 percent in the second quarter of 2005, compared
to 10.0 percent in 2004. Adjusted* S,G&A expense in the second
quarter of 2005 was $79.2 million, or 12.0 percent of sales,
compared to $63.4 million in the second quarter of 2004, or 9.5
percent of sales. As expected, the increase in the adjusted*
S,G&A primarily was driven by the ongoing, incremental costs
associated with being an independent, public company that were not
required when the business was part of Abbott. Income from
operations in the quarter was $98.2 million, compared to $180.2
million in the second quarter of 2004, which included a one-time,
non- cash curtailment gain of $64.6 million related to the
previously discussed benefit change. The operating margin for the
second quarter of 2005 was 14.8 percent, compared to 27.0 percent
for the same period in 2004. Adjusted* income from operations in
the quarter was $121.7 million, an increase of 1.4 percent from
$120.1 million in the second quarter of 2004. The adjusted*
operating margin for the second quarter of 2005 was 18.4 percent,
compared to 18.0 percent in 2004. The increase was attributable to
the improvement in gross margin, partially offset by higher R&D
and S,G&A spending. Interest expense in the second quarter of
2005 was $6.9 million, compared to $2.7 million in interest expense
in the same period of 2004. The 2005 quarter reflects a full
quarter of interest expense on Hospira's outstanding senior
unsecured notes. In the second quarter of 2004, Hospira only
incurred interest for the months of May and June, at lower average
interest rates. Other income was $3.5 million in the quarter,
compared to other expense of $0.5 million for 2004. The majority of
the change is due to higher interest income earned on cash
balances. Prior to the spin-off, Hospira, as part of Abbott, did
not hold cash. Net income in the quarter was $72.0 million,
compared to $125.8 million in the second quarter of 2004. Adjusted*
net income for the quarter increased 1.1 percent to $89.9 million,
from $88.9 million in 2004. The tax rate for the second quarter of
2005 was 24.0 percent, compared to 24.0 percent, excluding the
impact of the one-time curtailment gain, in the same quarter of
2004. Results by Geographic Segment Net sales in the United States
decreased 1.1 percent in the second quarter of 2005 to $549.4
million, from $555.5 million in the same quarter of 2004,
reflecting the impact of the "wind-down" of the Berlex agreement,
partially offset by other volume and mix gains. Income from
operations in the second quarter of 2005 was $92.7 million,
compared to $159.5 million last year, which included the one-time,
non-cash curtailment gain of $64.6 million. In the International
segment, net sales were $112.5 million, a 0.6 percent increase from
last year's $111.9 million, due to the benefit of foreign exchange.
Excluding the $4.0 million benefit from foreign currency
translation, net sales in the segment declined 3.1 percent,
primarily due to lower third-party sales. Income from operations in
the second quarter of 2005 was $20.5 million, compared to $34.5
million in the same quarter of 2004. Six-Month Results For the six
months ended June 30, 2005, consolidated net sales increased 2.7
percent to $1.32 billion, compared to $1.29 billion in the same
period of 2004. Net sales were favorably affected by foreign
currency translation of $8.1 million. Excluding the foreign
exchange impact, net sales increased 2.1 percent. Net income was
$149.2 million, compared to $190.8 million in the first six months
of 2004. Diluted earnings per share were $0.93, compared to $1.22
last year. Adjusted* net income was $177.1 million, compared to
$154.2 million last year. Adjusted* diluted earnings per share in
the first six months of 2005 were $1.11, compared to $0.98 in the
prior year. Cash Flow Items Cash flow from operations for the first
six months of 2005 was $300.2 million, compared to $219.6 million
in last year's same period. Depreciation and amortization expense
was $80.5 million for the first six months, compared to $69.8
million for the same period in 2004. The increase is due to higher
levels of capital spending and increased depreciation related to
the change in the fourth quarter of 2004 in the estimated useful
life for certain drug delivery pumps placed with customers. Capital
expenditures were $131.1 million for the first half of 2005,
compared to $108.3 million for the first half of 2004. The increase
is driven by spending related to building the company's independent
infrastructure, capacity expansion and ongoing projects. Updated
2005 Projections Hospira increased its projection for annual net
sales for the fiscal year 2005 to approximately $2.6 billion. The
company also increased its diluted earnings per share projection to
a range of $1.47 to $1.52, including estimated non-recurring
transition expenses described below and the charges related to the
transaction with ICU Medical. Adjusted* diluted earnings per share
for 2005, which exclude the non- recurring transition expenses and
the charges related to the ICU Medical transaction, are projected
to be in the range of $1.77 to $1.82. The reconciliation between
the projected adjusted* diluted earnings per share and earnings per
share on a GAAP basis is: Diluted earnings per share -- adjusted*
$1.77 - $1.82 Non-recurring transition expenses related to becoming
an independent, stand-alone company (mid-point of an estimated
$0.21 to $0.25 per diluted share range for 2005) ($0.23) Charges
for ICU Medical transaction ($15.8 million on a pre-tax basis)
($0.07) Diluted earnings per share -- GAAP basis $1.47 - $1.52 The
earnings per share projection on both a GAAP and adjusted* basis do
not include the effect of any future decision to repatriate foreign
earnings under the Jobs Creation Act of 2004, or the expensing of
stock options. The company expects to implement the accounting
standard related to stock option expensing on Jan. 1, 2006.
Additional information on selected income statement items is
outlined in the table below. Income Implied Projections for the
Statement 2005 Projections on Second Half of 2005 on Item an
Adjusted* Basis an Adjusted* Basis Net Sales Approximately $2.6
billion Approximately $1.3 billion Gross Margin Approximately 32.8%
to 33.3% Approximately 31.5% to 32.0% Research & Approximately
5.0% to 5.5% Approximately 5.8% to 6.3% Development of sales
S,G&A Approximately 12.0% to 12.5% Approximately 13.0% to 13.5%
of sales Interest Approximately $29 to Approximately $15 to Expense
$30 million $16 million Tax Rate Approximately 24.0% Approximately
24.0% Assumed Shares Outstanding For Diluted EPS Calculation
Approximately 161.5 million Approximately 163.0 million In
addition, the company projects that cash flow from operations will
be in the $425 million to $475 million range in 2005. Depreciation
and amortization for 2005 is projected to be in the $160 million to
$170 million range. Capital expenditures for 2005 are projected to
be in the $250 million to $275 million range. *Use of Non-GAAP
Financial Measures In addition to the results reported in
accordance with GAAP in the United States included within this
press release, Hospira has provided certain information that is
considered non-GAAP financial measures. As used in this press
release, "adjusted" refers to operating performance measures that
exclude the non-recurring transition expenses related to becoming
an independent, stand-alone company, charges related to the ICU
Medical transaction in 2005 and the one-time curtailment gain
reported in the year-to- date results for 2004. The adjusted
information is reconciled to its closest GAAP measure in accordance
with Securities and Exchange Commission Rules and is included in
the attached supplemental data. Management believes that these
non-GAAP financial measures are useful to both management and its
investors in their analysis of the company's ongoing business and
operating performance. Management also uses this information for
operational planning and decision-making purposes. Non-GAAP
financial measures should not be considered a substitute for any
GAAP measure. Additionally, non-GAAP financial measures as
presented by Hospira may not be comparable to similarly titled
measures reported by other companies. In the second quarter of
2005, Hospira incurred non-recurring pre-tax transition expenses of
$10.2 million ($7.7 million, or $0.05 per share, after tax) related
to establishing an independent infrastructure. The company has
previously stated that these non-recurring transition expenses are
expected to total approximately $100 million over the 24-month
period ending April 30, 2006. Of these costs, a total of $53.3
million has been incurred through June 30, 2005. Additionally, in
the second quarter of 2005 Hospira incurred a $13.4 million ($10.2
million, or $0.06 per share, after tax) charge for obligations
related to the sale of the Salt Lake City manufacturing facility.
Webcast A conference call for investors and media will be held at 9
a.m. Central Time, Thursday, Aug. 11, 2005. A live webcast of the
conference call will be available at
http://www.hospirainvestor.com/. Listeners should log on
approximately 10 minutes in advance to ensure proper computer setup
to receive the webcast. A replay will be available on the Hospira
Web site for 30 days following the call. About Hospira Hospira,
Inc. is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness(TM) by developing,
manufacturing and marketing products that help improve the
productivity, safety and efficacy of patient care. With 70 years of
service to the hospital industry, Hospira's portfolio includes one
of the industry's broadest lines of generic acute-care injectables,
which help address the high cost of proprietary pharmaceuticals in
hospitals; integrated solutions for medication management and
infusion therapy; and the leading U.S. injectable contract
manufacturing business. Headquartered in Lake Forest, Ill., north
of Chicago, Hospira has approximately 13,000 employees and 14
manufacturing facilities worldwide. Hospira's news releases and
other information can be found at http://www.hospira.com/. Private
Securities Litigation Reform Act of 1995 -- A Caution Concerning
Forward-Looking Statements Some statements in this news release may
be forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. Hospira cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Economic,
competitive, governmental, technological and other factors that may
affect Hospira's operations and may cause actual results to be
materially different from expectations include the risks and
uncertainties set forth under the heading "Item 1 Business -- Risk
Factors" in Hospira's Annual Report on Form 10-K for the year ended
Dec. 31, 2004, filed with the Securities and Exchange Commission,
which are incorporated by reference. Hospira undertakes no
obligation to release publicly any revisions to forward-looking
statements as the result of subsequent events or developments.
Hospira, Inc. Consolidated Statements of Income (Unaudited)
(dollars and shares in thousands, except for per share amounts)
Three Months Ended Six Months Ended June 30 % Change June 30 %
Change 2005 2004 2005 2004 Net sales $618,510 $617,367 0.2
$1,235,205 $1,192,565 3.6 Net sales to Abbott Laboratories 43,405
50,025 (13.2) 88,771 96,045 (7.6) Total Net Sales 661,915 667,392
(0.8) 1,323,976 1,288,610 2.7 Cost of products sold 443,497 456,765
(2.9) 887,782 909,644 (2.4) Gross Profit 218,418 210,627 3.7
436,194 378,966 15.1 Research and development 32,851 28,087 17.0
61,242 52,533 16.6 Selling, general and administrative 87,409
66,931 30.6 169,284 124,441 36.0 Curtailment of post-retirement
medical and dental benefits - (64,636) nm - (64,636) nm Income From
Operations 98,158 180,245 (45.5) 205,668 266,628 (22.9) Interest
expense 6,857 2,684 155.5 14,026 2,684 422.6 Other (income)
expense, net (3,476) 526 nm (4,681) 1,394 nm Income Before Income
Taxes 94,777 177,035 (46.5) 196,323 262,550 (25.2) Income tax
expense 22,746 51,265 (55.6) 47,117 71,789 (34.4) Net Income
$72,031 $125,770 (42.7) $149,206 $190,761 (21.8) Earnings Per
Common Share: Basic $0.45 $0.80 (43.8) $0.94 $1.22 (23.0) Diluted
$0.44 $0.80 (45.0) $0.93 $1.22 (23.8) Weighted Average Common
Shares Outstanding: Basic 158,568 156,048 1.6 157,896 156,048 1.2
Diluted 160,908 156,551 2.8 159,757 156,551 2.0 Hospira, Inc.
Reconciliation of Statements of Income (Unaudited) (dollars and
shares in thousands, except per share amounts) Three Months Ended
June 30, 2005 2004 GAAP Adjustments Adjusted GAAP Adjustments
Adjusted Net sales $618,510 $618,510 $617,367 $617,367 Net sales to
Abbott Laboratories 43,405 43,405 50,025 50,025 Total Net Sales
661,915 - 661,915 667,392 - 667,392 Cost of products sold 443,497
(15,230) A 428,267 456,765 (905) B 455,860 Gross Profit 218,418
15,230 233,648 210,627 905 211,532 Research and development 32,851
(112) B 32,739 28,087 (19) B 28,068 Selling, general and
administra- tive 87,409 (8,218) B 79,191 66,931 (3,546) B 63,385
Curtailment of post-retirement medical and dental benefits - - -
(64,636) 64,636 C - Income From Operations 98,158 23,560 121,718
180,245 (60,166) 120,079 Interest expense 6,857 - 6,857 2,684 2,684
Other (income) expense, net (3,476) - (3,476) 526 (189) 337 Income
Before Income Taxes 94,777 23,560 118,337 177,035 (59,977) 117,058
Income tax expense 22,746 5,655 28,401 51,265 (23,121) C 28,144 Net
Income $72,031 $17,905 $89,936 $125,770 $(36,856) $88,914 Earnings
Per Common Share: Basic $0.45 $0.11 $0.56 $0.80 $(0.24) $0.56
Diluted $0.44 $0.11 $0.55 $0.80 $(0.24) $0.56 Weighted Average
Common Shares Outstanding: Basic 158,568 158,568 158,568 156,048
156,048 156,048 Diluted 160,908 160,908 160,908 156,551 156,551
156,551 Statistics (as a % of Total Net Sales, except for income
tax rate) Gross Profit 33.0% 35.3% 31.6% 31.7% R&D 5.0% 4.9%
4.2% 4.2% SG&A 13.2% 12.0% 10.0% 9.5% Income From Operations
14.8% 18.4% 27.0% 18.0% Income Before Income Taxes 14.3% 17.9%
26.5% 17.5% Net Income 10.9% 13.6% 18.8% 13.3% Income tax rate
24.0% 24.0% 29.0% 24.0% % Change vs. Prior Year GAAP Adjusted Net
sales 0.2 0.2 Net sales to Abbott Laboratories (13.2) (13.2) Total
Net Sales (0.8) (0.8) Cost of products sold (2.9) (6.1) Gross
Profit 3.7 10.5 Research and development 17.0 16.6 Selling, general
and administrative 30.6 24.9 Curtailment of post-retirement medical
and dental benefits nm nm Income From Operations (45.5) 1.4
Interest expense 155.5 155.5 Other (income) expense, net nm nm
Income Before Income Taxes (46.5) 1.1 Income tax expense (55.6) 0.9
Net Income (42.7) 1.1 Earnings Per Common Share: Basic (43.8) 1.8
Diluted (45.0) (1.8) Weighted Average Common Shares Outstanding:
Basic 1.6 1.6 Diluted 2.8 2.8 A -- Includes non-recurring charges
of $13,404 related to the sale of the Salt Lake City manufacturing
plant to ICU Medical, and non-recurring transition costs of $1,826.
B -- Non-recurring transition costs. C -- 2004 Curtailment gain
($64,636) is tax effected at 37.5%, while second quarter of 2004
non-recurring transition costs were tax effected at 24%. Hospira,
Inc. Reconciliation of Statements of Income (Unaudited) (dollars
and shares in thousands, except per share amounts) Six Months Ended
June 30, 2005 2004 GAAP Adjustments Adjusted GAAP Adjustments
Adjusted Net sales $1,235,205 $1,235,205 $1,192,565 $1,192,565 Net
sales to Abbott Laboratories 88,771 88,771 96,045 96,045 Total Net
Sales 1,323,976 - 1,323,976 1,288,610 - 1,288,610 Cost of products
sold 887,782 (18,371) A 869,411 909,644 (991) B 908,653 Gross
Profit 436,194 18,371 454,565 378,966 991 379,957 Research and
development 61,242 (220) B 61,022 52,533 (30) B 52,503 Selling,
general and administra- tive 169,284 (18,137) B 151,147 124,441
(3,849) B 120,592 Curtailment of post-retirement medical and dental
benefits - - - (64,636) 64,636 C - Income From Operations 205,668
36,728 242,396 266,628 (59,766) 206,862 Interest expense 14,026
14,026 2,684 2,684 Other (income) expense, net (4,681) - (4,681)
1,394 (189) 1,205 Income Before Income Taxes 196,323 36,728 233,051
262,550 (59,577) 202,973 Income tax expense 47,117 8,815 55,932
71,789 (23,025) C 48,764 Net Income $149,206 $27,913 $177,119
$190,761 $(36,552) $154,209 Earnings Per Common Share: Basic $0.94
$0.18 $1.12 $1.22 $(0.24) $0.98 Diluted $0.93 $0.18 $1.11 $1.22
$(0.24) $0.98 Weighted Average Common Shares Outstanding: Basic
157,896 157,896 157,896 156,048 156,048 156,048 Diluted 159,757
159,757 159,757 156,551 156,551 156,551 Statistics (as a % of Total
Net Sales, except for income tax rate) Gross Profit 32.9% 34.3%
29.4% 29.5% R&D 4.6% 4.6% 4.1% 4.1% SG&A 12.8% 11.4% 9.7%
9.4% Income From Operations 15.5% 18.3% 20.7% 16.1% Income Before
Income Taxes 14.8% 17.6% 20.4% 15.8% Net Income 11.3% 13.4% 14.8%
12.0% Income tax rate 24.0% 24.0% 27.3% 24.0% % Change vs. Prior
Year GAAP Adjusted Net sales 3.6 3.6 Net sales to Abbott
Laboratories (7.6) (7.6) Total Net Sales 2.7 2.7 Cost of products
sold (2.4) (4.3) Gross Profit 15.1 19.6 Research and development
16.6 16.2 Selling, general and administrative 36.0 25.3 Curtailment
of post-retirement medical and dental benefits nm nm Income From
Operations (22.9) 17.2 Interest expense 422.6 422.6 Other (income)
expense, net nm nm Income Before Income Taxes (25.2) 14.8 Income
tax expense (34.4) 14.7 Net Income (21.8) 14.9 Earnings Per Common
Share: Basic (23.0) 14.3 Diluted (23.8) 12.2 Weighted Average
Common Shares Outstanding: Basic 1.2 1.2 Diluted 2.0 2.0 A --
Includes an impairment charge of $2,429 and other charges of
$13,404 related to the sale of the Salt Lake City manufacturing
plant to ICU Medical, and non-recurring transition costs of $2,538.
B -- Non-recurring transition costs. C -- 2004 Curtailment gain
($64,636) is tax effected at 37.5%, while first six months of 2004
non-recurring transition costs were tax effected at 24%. Hospira,
Inc. Consolidated Balance Sheets (Unaudited) (dollars in thousands)
June 30 December 31 Assets 2005 2004 Current Assets: Cash and cash
equivalents $424,681 $127,695 Marketable securities - 72,438 Net
trade receivables 317,928 326,356 Inventory 494,789 518,324 Prepaid
expenses, deferred income taxes and other receivables 161,590
153,512 Total Current Assets 1,398,988 1,198,325 Net property and
equipment 960,726 946,304 Intangible assets, net of amortization
621 1,057 Goodwill 80,973 80,973 Other assets 108,597 116,131 Total
Assets $2,549,905 $2,342,790 Liabilities and Shareholders' Equity
Current Liabilities: Trade accounts payable $96,779 $101,537
Salaries payable and other accruals 330,985 268,615 Due to Abbott,
net 122,469 166,042 Total Current Liabilities 550,233 536,194 Due
to Abbott, net - 23,100 Long-term debt 698,618 698,841
Post-retirement obligations, deferred income taxes and other
long-term liabilities 99,059 100,736 Commitments and Contingencies
- - Total Liabilities 1,347,910 1,358,871 Total Shareholders'
Equity 1,201,995 983,919 Total Liabilities and Shareholders' Equity
$2,549,905 $2,342,790 Hospira, Inc. Consolidated Statements of Cash
Flows (Unaudited) (dollars in thousands) Six Months Ended June 30
2005 2004 Cash Flow From (Used in) Operating Activities: Net income
$149,206 $190,761 Adjustments to reconcile net income to net cash
from operating activities-- Depreciation 79,606 67,639 Amortization
of intangibles 936 2,153 Curtailment of post-retirement medical and
dental benefits - (64,636) Trade receivables (812) (23,808)
Inventories 5,339 (37,275) Prepaid expenses and other assets
(5,721) (4,458) Trade accounts payable and other liabilities 20,729
85,020 Other, net 50,875 4,161 Net Cash From Operating Activities
300,158 219,557 Cash Flow (Used in) From Investing Activities:
Acquisitions of property and equipment (131,089) (108,347) Proceeds
from asset dispositions 31,818 - Sale of marketable securities
72,438 - Net Cash (Used in) Investing Activities (26,833) (108,347)
Cash Flow From (Used in) Financing Activities: Net transactions
with Abbott Laboratories prior to spin-off - (20,845)
Pre-distribution dividend to Abbott - (700,000) Payment to Abbott
for international net assets (45,768) - Issuance of long-term debt,
net of fees paid 1,750 1,393,425 Repayment of long-term debt (44)
(700,000) Net change in revolving credit facility - 25,000 Proceeds
from stock options exercised 70,255 103 Net Cash From (Used in)
Financing Activities 26,193 (2,317) Effect of exchange rate changes
on cash and cash equivalents (2,532) (13) Net change in cash and
cash equivalents 296,986 108,880 Cash and cash equivalents at
beginning of period 127,695 - Cash and cash equivalents at end of
period $424,681 $108,880 Hospira, Inc. Sales by Product Line
(Unaudited) (dollars in millions) Three Months Ended Six Months
Ended June 30 June 30 Percent Percent Change Change vs. Prior vs.
Prior 2005 2004 Year* 2005 2004 Year* U.S. -- Specialty Injectable
Pharmaceuticals $201 $221 (9.2) $426 $426 (0.1) Medication Delivery
Systems 204 192 6.2 393 379 3.5 Injectable Pharmaceutical Contract
Manufacturing 52 46 13.6 102 84 22.0 Sales to Abbott Laboratories
27 34 (21.0) 55 71 (21.9) Other 65 62 5.1 124 117 6.6 Total U.S.
549 555 (1.1) 1,100 1,077 2.2 International -- Sales to Third
Parties 96 96 0.1 190 187 2.1 Sales to Abbott Laboratories 17 16
3.2 34 25 31.6 Total International Sales 113 112 0.6 224 212 5.7
Consolidated Net Sales $662 $667 (0.8) $1,324 $1,289 2.7 * Percent
change computed based on unrounded numbers. Note: Consolidated Net
Sales for second quarter and year-to-date include the favorable
impact of 1.5% and 1.0%, respectively, related to the change in
business model in late 2004, which resulted in sales-type lease
accounting for new pump leases. Hospira, Inc. Segment Information
(Unaudited) (dollars in thousands) Three Months Ended June 30 Net
Sales Income from Operations 2005 2004 % Change 2005 2004 (1) %
Change U.S. $549,380 $555,501 (1.1) $92,674 $159,515 (41.9)
International 112,535 111,891 0.6 20,539 34,480 (40.4) Total
reportable segments $661,915 $667,392 (0.8) 113,213 193,995 (41.6)
Corporate functions (15,055) (13,750) 9.5 Income from operations
98,158 180,245 (45.5) Other, net (3,381) (3,210) nm Income before
income taxes $94,777 $177,035 (46.5) Six Months Ended June 30 Net
Sales Income from Operations 2005 2004 % Change 2005 2004 (1) %
Change U.S. $1,099,770 $1,076,432 2.2 $190,826 $239,639 (20.4)
International 224,206 212,178 5.7 42,192 51,832 (18.6) Total
reportable segments $1,323,976 $1,288,610 2.7 233,018 291,471
(20.1) Corporate functions (27,350) (24,843) 10.1 Income from
operations 205,668 266,628 (22.9) Other, net (9,345) (4,078) nm
Income before income taxes $196,323 $262,550 (25.2) (1) 2004 U.S.
Income from operations includes curtailment benefit of $65 million.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Media, Stacey Eisen, +1-224-212-2276, or Financial Community, Lynn
McHugh, +1-224-212-2363, both of Hospira, Inc. Web site:
http://www.hospira.com/ http://www.hospirainvestor.com/
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024